A Phase 4 Pragmatic, Randomized Trial to Evaluate the Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19

The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of the COVID-19 vaccine, mRNA-1273, in adults aged 50-64 years without known risk factors for severe COVID-19 infection. Participants will be randomized 1:1 to either COVID-19 vaccine or no COVID-19 vaccine.

Start Date11 Dec 2025

Sponsor / Collaborator

Herlev and Gentofte Hospital

[+1]

NCT07266558

/ Active, not recruitingPhase 4

A Phase 4, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of mRNA-1283 And mRNA-1273 Variant-Containing Formulation in Adults 50 to 64 Years of Age Without Underlying Conditions That Put Them at High Risk for Severe Outcomes From COVID-19

The purpose of this study is to evaluate the efficacy and safety of mRNA-1283 and mRNA-1273 (variant formulations) in adults 50 to 64 years of age without high risk factors for severe COVID-19.

Start Date26 Nov 2025

Sponsor / Collaborator

ModernaTX, Inc.

NCT06585241

/ RecruitingPhase 4

A Phase 3b/4, Open-label Study to Assess the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Start Date09 Sep 2024

Sponsor / Collaborator

ModernaTX, Inc.

100 Clinical Results associated with Elasomeran

100 Translational Medicine associated with Elasomeran

100 Patents (Medical) associated with Elasomeran

2,190

Literatures (Medical) associated with Elasomeran

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Modeling the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in the United States

Article

Author: Kohli, Michele ; Fust, Kelly ; Van de Velde, Nicolas ; Joshi, Keya ; Cartier, Shannon ; Beck, Ekkehard ; Lee, Amy ; Weinstein, Milton

AIMS:

COVID-19 disease burden in United States (US) adults ≥65 years and persons with underlying medical conditions remains high. This modeling study estimated the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in persons aged 12-64 at high risk of severe COVID-19 outcomes and all adults ≥65 years.

METHODS:

mRNA-1283 was compared with no annual vaccination and originally licensed mRNA vaccines mRNA-1273 and BNT162b2. Analyses were conducted using a static decision-analytic model (1-year horizon). Vaccine effectiveness (VE) against infection and hospitalization for mRNA-1283 versus no vaccination was based on relative VE (rVE) from the Phase 3 pivotal randomized controlled trial comparing mRNA-1283 against mRNA-1273, and mRNA-1273 real-world data. rVE estimates for mRNA-1283 versus BNT162b2 were based on an indirect treatment comparison. The societal incremental cost per quality-adjusted life-year (QALY) gained and the benefit-cost ratio (BCR) were calculated.

RESULTS:

During the 2025/2026 season, a single dose of mRNA-1283 was estimated to yield an incremental cost per QALY gained of $16,247 compared with no vaccine. The BCR for the base case strategy ranged from $2.16-9.74 returned for every $1 spent for mRNA-1283. mRNA-1283 was estimated to dominate originally-licensed mRNA-COVID-19 vaccines in analyses of the target population. Results were sensitive to COVID-19 incidence, hospitalization rates, post-discharge mortality rates, and VE.

LIMITATIONS:

The real-world effectiveness and safety of mRNA-1283 have not yet been established, and relative VE estimates should be validated with real-world data. Full year 2025/2026 COVID-19 incidence and vaccine uptake in the US is uncertain.

CONCLUSIONS:

Study results suggest mRNA-1283 may represent a highly cost-effective strategy (considering a $100,000-150,000 per QALY willingness-to-pay threshold) to reduce COVID-19 burden. Based on rVE assumptions made, mRNA-1283 was estimated to dominate originally-licensed mRNA vaccines in this recommended population. mRNA-1283 may provide a valuable option to optimize US COVID-19 immunization programs and protect those most vulnerable.

31 Dec 2026·Human Vaccines & Immunotherapeutics

From discovery through emergency use to the present: Safety evaluation of the COVID-19 mRNA-1273 (Moderna) vaccine

Review

Author: Straus, Walter

The COVID-19 pandemic created an urgent need to develop preventive vaccines to blunt the impact of the greatest global health crisis in a century. Two vaccines, both employing mRNA technology, were developed from bench to bedside in under one year - a milestone considered nearly impossible. This paper examines the evolving safety profile of mRNA-1273, from development under Operation Warp Speed through Emergency Use Authorization, and subsequent deployment at nearly unprecedented scale. Vaccine safety was characterized during clinical development and refined through well-established safety monitoring systems (e.g. Vaccine Adverse Event Reporting System [VAERS]), as well as newly introduced systems such as V-Safe. Key safety findings, such as myocarditis, are reviewed as well as safety findings in special populations. The complementary contributions of public, private, and academic sectors highlight how collaboration and rigorous monitoring supported timely and comprehensive safety assessment of a new vaccine in the extraordinary setting of a global pandemic.

31 Dec 2026·Human Vaccines & Immunotherapeutics

Hematologic adverse events following COVID-19 vaccination and revaccination in persons aged 12 and above: A Canadian Immunization Research Network study

Article

Author: Lam, Godfrey ; McHenry, Mary ; Barber, Colin ; Castellucci, Lana A. ; Rosenfield, Lana ; Belga, Sara ; Deeks, Shelley ; Rex, Greg ; Sadarangani, Manish ; Cameron, Scott B. ; Roches, Anne Des ; Constantinescu, Cora ; Zaborniak, Karver ; Bosonea, Ana ; Viel-Theriault, Isabelle ; Cowan, Juthaporn ; Pham-Huy, Anne ; Finlay, Jane ; McConnell, Athena ; Chew, Jo Lin ; Vaudry, Wendy ; Lacuesta, Gina ; Quach, Caroline ; Abdurrahman, Zainab ; McNeil, Shelly ; Halperin, Scott ; Morris, Shaun K. ; De Serres, Gaston ; Mah, Allison ; Wilson, Sarah ; Burton, Catherine ; Pernica, Jeffrey M. ; Naus, Monika ; Hildebrand, Kyla ; Grant, Ian ; Chapdelaine, Hugo ; Pourshahnazari, Persia ; Salvadori, Marina ; Gantt, Soren ; Buchan, C. Arianne ; Falcone, Emilia ; Piche-Renaud, Pierre-Philippe ; Rubin, Tamar ; Kalicinsky, Chrystyna ; Kanani, Amin ; Suresh, Sneha ; Top, Karina A. ; Morris, Shaun ; Shivakumar, Sundeep ; Drolet, Jean-Philippe ; Blaquiere, Martin ; Upton, Julia ; Mak, Raymond ; Betschel, Stephen ; Comeau, Jeannette ; Salvo, Grazia ; Simons, Elinor ; Sturtevant, Doris ; Cook, Victoria ; Wright, Alissa ; Vostretsova, Kateryna ; Song, Christine ; Gagnon, Remi ; Carignan, Alex ; Smolinski, Michael ; Fitzpatrick, Tiffany

Data on safety of revaccination after a hematologic adverse event following immunization (AEFI) with COVID-19 vaccines are limited. This study characterized hematologic AEFIs in patients assessed by Canadian Special Immunization Clinic (SIC) network physicians from January 2021 to February 2023 and estimated recurrence rates of hematologic events after revaccination. Following clinical assessment of 475 individuals, revaccinated participants were followed for recurrence of AEFI. Thirty-eight cases (21 [55.3%] males and 17 [44.7%] females) with hematologic AEFIs and aged ≥12 were included in the analysis; 31/38 participants (81.6%) were 18 to 64 y old. Immune thrombocytopenia, deep vein thrombosis and pulmonary embolism were the most common diagnoses, accounting for 11 (28.9%), 9 (23.7%) and 9 (23.7%), cases. Two cases of thrombosis with thrombocytopenia syndrome (TTS) were reported after ChAdOx1. The vaccines associated with hematologic AEFIs were BNT162b2 (17, 44.7%), ChAdOx1 (11, 28.9%), and mRNA-1273 (10, 26.3%). Twenty-seven (71.1%) participants were revaccinated; 14 (51.9%) received the same vaccine product as their initial vaccine while 13 (48.1%) received a different product. There were no recurrences of the same AEFI reported after revaccination with an mRNA vaccine, including the two patients with TTS, suggesting that hematologic AEFI recurrences following COVID-19 vaccines are likely uncommon.

995

News (Medical) associated with Elasomeran

01 Jun 2026

·www.fiercepharma.com

Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative

The FDA delivered its green light more than two weeks early, with the agency originally slated to weigh in on Shionogi’s Xocova application by June 16. After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. patients, Shionogi has secured an FDA green light for the medicine in the prevention setting.Sold under the Xocova moniker—and available in Japan since 2022—Shionogi’s oral drug has been cleared for post-exposure prophylaxis (PEP) of COVID-19 in U.S. adults and adolescents ages 12 and older following contact with someone who has COVID.With the FDA's sign-off, Xocova has earned the distinction of becoming the first oral drug approved in the U.S. to protect against COVID after exposure, Shionogi noted in a June 1 press release. The drug is taken over five days, beginning with three tablets on day one and just one tablet on the following four. The FDA delivered its green light more than two weeks early, with the agency originally slated to weigh in on Shionogi’s Xocova application by June 16. Beyond currently approved COVID-19 vaccines from Pfizer-BioNTech, Moderna and Novavax, the U.S. has also cleared antiviral treatments in Pfizer’s Paxlovid, Gilead’s Veklury and Merck & Co.’s Lagevrio, all for treatment after symptom onset. Shionogi’s drug, meanwhile, “has the potential to benefit anyone who does not want to get COVID-19,” Frederick Hayden, M.D., professor emeritus of clinical virology at the University of Virginia School of Medicine, said in the company’s release. Aside from use among households, Xocova could offer an appealing prophylactic option in other exposure incidents, including outbreaks in nursing homes and care facilities, and after travel-related contact, Hayden added. The FDA’s approval hinges on Shionogi’s SCORPIO-PEP trial, in which Xocova curbed the risk of symptomatic COVID-19 by 67% in uninfected people following exposure to someone infected, through 10 days, as weighted against placebo. Shionogi’s trial enrolled 2,387 participants who had a negative local screening test for the SARS-CoV-2 virus and no symptoms at enrollment after being exposed to an infected person in their household. The company’s primary analysis relied on 2,041 household contact participants with a lab-confirmed negative test at baseline. The Osaka-headquartered company noted that its antiviral was generally well tolerated, with headache, diarrhea and cough the most common side effects among patients on Xocova. “Xoxova is the first and only oral option clinically proven to help prevent symptomatic COVID-19 after exposure among study participants regardless of vaccination status or baseline immunity from prior infection,” Nathan McCutcheon, president and CEO of Shionogi’s U.S. arm, said in a statement. With the drug, “people who are exposed to COVID-19 can act early to help protect themselves,” he added. While the heyday of COVID-19 vaccine and drug sales has long waned—as evinced by Pfizer and Moderna’s ongoing earnings pressures—Shionogi feels Xocova still has an important niche to fill as the disease remains highly transmissible. Up to 47% of people who live with someone infected with COVID risk developing it themselves, Shionogi reckons, pointing to CDC estimates that there were some 3.8 million to 12.4 million new COVID cases in the U.S. from the beginning of last October to May 23, 2026. These infections led to hundreds of thousands of outpatient visits, some 240,000 hospitalizations and between 13,000 and 42,000 deaths, according to the data. In Shionogi’s home country of Japan, Xocova also holds a post-exposure prophylaxis approval. The antiviral was originally greenlit under an emergency nod there as a COVID-19 treatment in November 2022 before securing a full approval in that setting in early 2024. The medication is also available in Singapore. With its protection nod, Shionogi has found a new niche in the U.S. market for Xocova, which disappointed in the late-stage SCORPIO-HR trial back in May 2024. In the study, the antiviral failed to chart a statistically significant reduction in time to sustained resolution of 15 common COVID symptoms. That performance caused the study to miss its primary endpoint. Shionogi leadership admitted at the time that the data were mixed, but they stood behind their asset’s potential and pledged to continue working with regulators to make ensitrelvir more broadly available. Shionogi clarified in its approval announcement Monday that Xocova is cleared as a preventative and not on offer as a COVID treatment in the U.S.

Drug ApprovalVaccineEmergency Use AuthorizationClinical Result

01 Jun 2026

·www.biospace.com

Moderna partners with CEPI on Ebola vaccine efforts amid outbreak in Africa

iStock/ Mongkol Akarasirithada Riding a newfound surge of interest on infectious disease concerns, Moderna is linking up with a global vaccine foundation in hopes of developing a vaccine to slow the new surge in Ebola underway in the Congo and Uganda. The Coalition for Epidemic Preparedness Innovations is investing up to $50 million for early-stage testing of Moderna’s experimental Ebola vaccine as suspected deaths from the latest outbreak surpass 200. CEPI’s commitment to Moderna will fuel preclinical activities and Phase 1 studies for the mRNA candidate targeting Bundibugyo ebolavirus (BDBV), one of several virus strains that cause the rare and severe Ebola disease—and the form currently circulating in the Democratic Republic of the Congo (DRC) and Uganda. There are currently no approved vaccines or candidates in clinical development that target BDBV. At the same time, CEPI’s money will support manufacturing efforts that would allow for the immediate launch of large Phase 2/3 trials if Phase 1 data supports further development, according to a Monday release . Vaccines Moderna’s stock rides hantavirus fears as spotlight returns to infectious disease platform While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers. May 20, 2026 · 4 min read · Nick Paul Taylor Read more Moderna’s early-stage program is built off the same mRNA technology used to rapidly create and scale Spikevax, the company’s COVID-19 vaccine that was bolstered by the U.S. government to help curb the pandemic that swept the world in 2020. The new pact expands on an existing alliance between Moderna and CEPI formed in late 2023 and focused on Moderna’s mRNA platform and accelerating countermeasures for potential epidemic and pandemic threats. The investment comes on the heels of a rough year for Moderna as the Trump administration’s health agencies shifted positions on vaccines, prompting the company to discontinue investment for late-stage vaccine studies of infectious diseases earlier this year. But concerns surrounding the recent hantavirus outbreak have pushed up Moderna’s stock and sent a reminder about the company’s past ability to protect against pandemics. As for CEPI, the global foundation is also investing in two other preclinical vaccine candidates targeting BDBV: up to $3.2 million for the non-profit International AIDS Vaccine Initiative and up to $8.6 million for a candidate from the University of Oxford that’s manufactured at the Serum Institute of India. The latter stems from the English university’s ChAdOx1 platform that underpinned the Oxford/AstraZeneca COVID-19 vaccine Vaxzevria, which has since been withdrawn from the market for commercial reasons. All the CEPI-chosen platforms have extensive safety data and have been used to develop vaccine candidates that have demonstrated efficacy against related filoviruses, a family of viruses that cause severe hemorrhagic fevers, according to the organization. Other filovirus conditions include Zaire ebolavirus, Sudan virus and Marburg virus. Over 900 suspected Ebola cases have been tallied so far amid the ongoing outbreak, which is the third largest filovirus outbreak ever, according to CEPI. “With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease,” CEPI CEO Richard Hatchett said in Monday release . “CEPI’s urgent funding and support aims to advance safe, effective vaccines to help control this epidemic.”

27 May 2026

·www.biospace.com

FDA assembles vaccine experts to update COVID-19 formulation

iStock, Vladimir Mandic The FDA will convene its vaccines advisory panel to discuss seasonal COVID-19 vaccines—a surprise move after Health Secretary and vaccine skeptic Robert F. Kennedy, Jr. overhauled a separate vaccine committee. The FDA will convene its Vaccines and Related Biological Products Advisory Committee to discuss possibly updating COVID-19 vaccines to include the now-dominant XFG subvariant. The meeting will take place on Thursday, May 28. The session will be a whole-day affair, during which the external experts will hear from the CDC and an independent working group from the World Health Organization, according to a draft agenda posted on the FDA’s website. The U.S. withdrew from the WHO in January. Vaccine developers Moderna, Sanofi and Pfizer will also be at the meeting to present updates from their respective products, per the federal documents. The FDA’s VRBPAC has convened several times over the years—once during the second Trump administration—to evaluate strain selection and vaccine formulation. During its May 2025 meeting , the vaccines advisory committee unanimously voted to recommend monovalent COVID-19 vaccines targeting the JN.1 lineage of the virus, according to a briefing document posted Tuesday. But the latest data from the CDC show that the XFG subvariant has now become the dominant type of virus circulating in the U.S. “More than six years after its emergence, SARS-CoV-2 is evolving against an increasingly heterogeneous immune landscape,” the FDA’s briefing document reads, pointing to varying levels of virus exposure, vaccination adherence and waning immunity across the country. The VRBPAC will be tasked with making a recommendation for a COVID-19 vaccine formulation against this backdrop, the FDA said. “All licensed manufacturers have indicated that they are prepared to produce an XFG vaccine for COVID-19 vaccines,” the agency added. FDA After ‘most damaging period in FDA history,’ Makary will be hard to replace With Commissioner Marty Makary’s exit, the FDA will enter a period of “unprecedented” and “prolonged” leadership vacuum, analysts at Capital Alpha predicted, noting that the government will have trouble finding someone who will want to take the FDA’s reins. May 13, 2026 · 3 min read · Tristan Manalac Read more The COVID-centric meeting comes shortly after the resignation of former FDA Commissioner Marty Makary—a known critic of COVID-19 vaccines. In his first public interview as FDA chief in April 2025, he claimed that the agency downplayed the side effects of COVID-19 shots, leading to what he called the “epidemic of distrust” against the regulator. A month later, he unwrapped a risk-based approach to approving COVID-19 vaccines, noting that moving forward, the regulator would focus on products for adults 65 and older and high-risk patients with underlying conditions. Makary penned this new risk-based framework with Vinay Prasad, former director of the Center for Biologics Evaluation and Research, and a similarly vocal critic of COVID-19 vaccines. Late last year, Prasad wrote an internal memo —that was subsequently leaked—claiming that “at least” 10 children have died “because” of COVID-19 vaccines. “For the first time, the US FDA will acknowledge that COVID-19 vaccines have killed American children,” he wrote at the time. Detailed data from the agency have since shown that Prasad’s claims were overblown , and that no pediatric deaths have been definitively linked to the shots. Prasad left the FDA at the end of April. Health Secretary Robert F. Kennedy, Jr . is himself a major skeptic of vaccines. Last May, for instance, Kennedy removed COVID-19 shots from the regular immunization guidelines for healthy pregnant women and healthy children. A few weeks later, he emptied the CDC’s vaccines advisory panel in a move he said at the time was “necessary to reestablish public confidence in vaccine science.” He has since reformed this group, called the Advisory Committee on Immunization Practices, filling it with experts who share his skepticism toward vaccines. vaccines In ‘Bold’ Move, RFK Jr. ‘Retires’ All 17 Members of CDC’s Vaccine Committee Two weeks of upheaval at the CDC culminated Monday in the complete reconstitution of the CDC’s Advisory Committee on Immunization Practices as HHS Secretary Robert F. Kennedy Jr. pens op-ed criticizing “conflicts of interest” he says exist on the current committee. June 9, 2025 · 2 min read · Heather McKenzie Read more

VaccineExecutive Change

100 Deals associated with Elasomeran

External Link

KEGG	Wiki	ATC	Drug Bank
-	Elasomeran	J07	DB15654

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
COVID-19 omicron variant infection	United Kingdom	Moderna, Inc.	15 Aug 2022
COVID-19	Canada	Moderna, Inc.	23 Dec 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05815498 (NextCOVE, CTgov)	Phase 3	COVID-19	13,553	mRNA-1283.222 (Part 1: mRNA-1283.222)	xqmlbhreqg(zbnvnlqijj) = rrefdhhfkk mpcyljubve (syupmimcak, qryavpwtpi - iszttpqojc) View more	-	01 May 2026
				mRNA-1273.222 (Part 1: mRNA-1273.222)	xqmlbhreqg(zbnvnlqijj) = dcykjlfycy mpcyljubve (syupmimcak, ovewfmmiar - radrpkdgpb) View more
NCT05077254 (CPAT-ISR, CTgov)	Phase 2	COVID-19 \| Renal transplant rejection \| Liver transplant rejection	48	COVID-19 Vaccine (Additional mRNA COVID-19 Vaccine Without ISR)	zgrbjrmozt(rltgbzcwav) = ujrmdqkqpe lmaolbhetm (foulvagaha, nwvvajpyxk - eopmuwaumu) View more	-	23 Apr 2026
				COVID-19 Vaccine (Additional mRNA COVID-19 Vaccine With ISR)	zgrbjrmozt(rltgbzcwav) = igjzthblfq lmaolbhetm (foulvagaha, nusmbdrhta - njudypazal) View more
NCT05160766 (EU-COVAT-1 \| VACCELERATE \| EU-COVAT-1_AGED, CTgov)	Phase 2	COVID-19	323	Comirnaty (BNT162b2 (Part A))	aqwuajkziw = iegdxnjwni nislnzjoyu (raivrbckac, fydvxnksta - oykogkutuk) View more	-	20 May 2025
				Spikevax (mRNA-1273 (Part A))	aqwuajkziw = btvfgkrmpe nislnzjoyu (raivrbckac, rbzmivikeg - adyzqmgmzh) View more
NCT05280158 (CTgov)	Phase 1/2	COVID-19	19	mRNA-1273 (Moderna COVID-19 vaccine) (Standard-dose)	quzntywdju = mmrsiwrnyl bgecuiliuw (jrqckxaest, vnsjjazcja - wmxlsthxwc) View more	-	26 Mar 2025
				mRNA-1273 (Moderna COVID-19 vaccine) (Mid-Dose)	quzntywdju = nvthsjxlok bgecuiliuw (jrqckxaest, wlguwpxwwy - xvcfngltvm) View more
NCT05022329 (BOOST KIDNEY, CTgov)	Phase 2/3	COVID-19 \| Chronic kidney disease, Stage V \| Chronic Kidney Diseases	273	BNT162b2 (Third Dose BNT162b2)	filewbyyuk(vplnaxmdbs) = vdenlamqfx miunumqsim (brzsrrjihh, 0.334) View more	-	19 Feb 2025
				mRNA-1273 (Moderna) (Third Dose mRNA-1273)	filewbyyuk(vplnaxmdbs) = ahnclcvrrg miunumqsim (brzsrrjihh, 0.169) View more
NCT05168813 (CoVPN 3008 (Ubuntu), Pubmed \| EClinicalMedicine)	Phase 2/3	HIV Infections HIV \| SARS-CoV-2 seropositive \| CD4 count ... View more	-	mRNA-1273 (Hybrid immunity group)	vhefyjwgxa(cinmmsgvji) = nsdrfmtfxy ljcouklray (nhehslnlqi ) View more	Positive	01 Feb 2025
				Vaccine immunity group	dgldtetbyi(kyhmwlivir) = wwzqwgspro nlrnhfvyja (vnaiofsbrk, 2.30 - 4.49) View more
NCT05047770 (Pubmed) Manual	Phase 3	Herpes Zoster	497	mRNA-1273quFlu D-QIVt influenza vaccine (QIV)	anhvnmpgnv(nssxnpgmbp) = The most frequently reported adverse events in both groups were pain at the injection site and myalgia. jmnrdxtwwy (wzlsnqimuu ) View more	Non-inferior	31 Dec 2024
				mRNA-1273 + Flu D-QIV(CoAd )
NCT05228730 (MIACoV, CTgov)	Phase 3	COVID-19	13	Tozinameran - Standard dose (Standard Pfizer-BioNTech Booster Group)	waodjhfifs(ituvsiazhb) = ydsnpjinpq apkoiojhtu (asdtskrqud, jzxfrqjiqb - hbvjajbkyt) View more	-	16 Dec 2024
				Tozinameran - fractional dose (Fractional Pfizer-BioNTech Booster Group)	waodjhfifs(ituvsiazhb) = sxkupiedxr apkoiojhtu (asdtskrqud, rcsxahxneh - dvcryqtzby) View more
NCT05249829 (CTgov)	Phase 2/3	COVID-19	3,548	mRNA-1273.529 (Part 1: mRNA-1273.529)	sbuusopyma(hmhlbddoup) = irjdlzdmmn srdxxyyfmi (apzktbrhwf, kwudqhzsdd - vxqrlpdxar) View more	-	09 Aug 2024
				mRNA-1273 (Part 1: mRNA-1273)	sbuusopyma(hmhlbddoup) = wwzrhrcacz srdxxyyfmi (apzktbrhwf, hsxqxilbcu - cmzbvusrcv) View more
NCT05160766 (VACCELERATE, Pubmed)	Phase 2	COVID-19	269	BNT162b2	kfnxeolwvj(cqkcmeqbso) = tjffqvxtai nytwhbvpca (uxuqtvpyzz ) View more	Positive	09 Jul 2024
				Elasomeran+mRNA (迪纳元昇)	kfnxeolwvj(cqkcmeqbso) = ovdywzpdhw nytwhbvpca (uxuqtvpyzz ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis